{"paper_id":"184248e6-b1e8-498a-b466-5d34f46ac3a7","body_text":"Abstract\nPurpose\nAdenomyosis is a diffuse or localized disease. Our previous study has indicated that tanshinone IIA (TSIIA) inhibits the proliferation, migration, and induces apoptosis of ectopic endometrial stromal cells (EESCs) of adenomyosis. However, the complex molecular mechanism of TSIIA in adenomyosis remains unclear. The objective of this study was to explore the complex molecular mechanism of TSIIA on EESCs.\nMethods\nIn our present study, we used the proteomics approach iTRAQ (isobaric tags for relative and absolute quantitation) combined with LC–MS/MS (liquid chromatography–mass spectrometry) to investigate changes in the protein profile of EESCs treated with TSIIA. Differential proteins were analyzed by employing bioinformatics tools and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. In TSIIA treated EESCs, the protein expression levels of TNFRSF10D, PLEKHM1, FECH, and TPM1A were detected by western blotting.\nResults\nQuantitative results revealed 267 significantly differential proteins in TSIIA pretreated EESCs. Gene Ontology (GO) analysis presented an overview of dysregulated proteins in the biological process (BP), cell component (CC), and molecular function (MF) categories. Interestingly, we observed that differential proteins in the extracellular matrix (ECM)-receptor interaction pathway and estrogen signaling pathway were all involved in the focal adhesion pathway, which plays essential roles in the TSIIA-mediated inhibition of EESC proliferation and migration.\nFurthermore, some significantly differential proteins, which may be potential targets for the treatment of adenomyosis in the future, were validated by western blotting.\nConclusions\nOur study provides a useful method to detect the detailed mechanism underlying the efficacy of TSIIA on EESCs.\nSimilar content being viewed by others\nReferences\nOliveira MAP, Crispi CP Jr, Brollo LC et al (2018) Surgery in adenomyosis. Arch Gynecol Obstet 297(3):581–589\nOsada H (2018) Uterine adenomyosis and adenomyoma: The surgical approach. Fertil Steril 109(3):406–417\nGarcia-Solares J, Donnez J, Donnez O et al (2018) Pathogenesis of uterine adenomyosis: invagination or metaplasia? Fertil Steril 109(3):371–379\nHarmsen MJ, Wong CFC, Mijatovic V et al (2019) Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review. Hum Reprod Update 25(5):647–671\nVannuccini S, Tosti C, Carmona F et al (2017) Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod Biomed Online 35(5):592–601\nAgostinho L, Cruz R, Osorio F et al (2017) MRI for adenomyosis: a pictorial review. Insights Imaging 8(6):549–556\nTellum T, Nygaard S, Lieng M (2020) Noninvasive diagnosis of adenomyosis: a structured review and meta-analysis of diagnostic accuracy in imaging. J Minim Invasive Gynecol 27(2):408–418\nTsui KH, Lee FK, Seow KM et al (2015) Conservative surgical treatment of adenomyosis to improve fertility: Controversial values, indications, complications, and pregnancy outcomes. Taiwan J Obstet Gynecol 54(6):635–640\nHuang L, Ji X, Wang X et al (2020) Adjuvant therapy of Chinese herbal medicine for the treatment of adenomyosis: A protocol for systematic review. Med Baltim 99(25):e20560\nBaboo KD, Chen Z, Zhang X (2019) Progress on medical treatment in the management of adenomyosis. Zhejiang Da Xue Xue Bao Yi Xue Ban 48(2):142–147\nMaybin JA, Critchley HO (2016) Medical management of heavy menstrual bleeding. Womens Health (Lond) 12(1):27–34\nRen J, Fu L, Nile SH et al (2019) Salvia miltiorrhiza in treating cardiovascular diseases: a review on its pharmacological and clinical applications. Front Pharmacol 10:753\nLi ZM, Xu SW, Liu PQ (2018) Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics. Acta Pharmacol Sin 39(5):802–824\nMa J, Hou D, Wei Z et al (2019) Tanshinone IIA attenuates cerebral aneurysm formation by inhibiting the NFkappaBmediated inflammatory response. Mol Med Rep 20(2):1621–1628\nYing Q, Teng Y, Zhang J et al (2019) Therapeutic effect of tanshinone IIA on liver fibrosis and the possible mechanism: a preclinical meta-analysis. Evid Based Complement Altern Med 2019:7514046\nCheng W, Xiang W, Wang S et al (2019) Tanshinone IIA ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection and autophagy promotion. Am J Transl Res 11(5):3140–3149\nRen X, Wang C, Xie B et al (2017) Tanshinone IIA induced cell death via miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol 796:233–241\nShang Q, Xu H, Huang L (2012) Tanshinone IIA: a promising natural cardioprotective agent. Evid Based Complement Altern Med 2012:716459\nWan L, Zou Y, Wan LH et al (2015) Tanshinone IIA inhibits the proliferation, migration and invasion of ectopic endometrial stromal cells of adenomyosis via 14-3-3zeta downregulation. Arch Gynecol Obstet 292(6):1301–1309\nWisniewski JR, Zougman A, Nagaraj N et al (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362\nBatth TS, Francavilla C, Olsen JV (2014) Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. J Proteome Res 13(12):6176–6186\nWang Y, Yang F, Gritsenko MA et al (2011) Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 11(10):2019–2026\nZhang X, Wang Q, Wang X et al (2019) Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother 112:108599\nYang L, Zhang B, Yin L et al (2011) Tanshinone IIA prevented brain iron dyshomeostasis in cerebral ischemic rats. Cell Physiol Biochem 27(1):23–30\nHuang L, Ding W, Wang MQ et al (2019) Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4. J Int Med Res 47(10):5239–5255\nLi D, Wang J, Sun D et al (2018) Tanshinone IIA sulfonate protects against cigarette smoke-induced COPD and down-regulation of CFTR in mice. Sci Rep 8(1):376\nLiu Z, Zhu W, Kong X et al (2019) Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer. Oncol Rep 42(5):1893–1903\nChen ZZ, Gong X (2020) Tanshinone IIA contributes to the pathogenesis of endometriosis via renin angiotensin system by regulating the dorsal root ganglion axon sprouting. Life Sci 240:117085\nLi N, Yang L, Zhang B et al (2018) Tanshinone IIA effects on ovarian cancer cell line. J Pharm Pharmacol 70(10):1369–1377\nLiu H, Lang J, Wang X et al (2008) Comparative proteomic analysis of human adenomyosis using two-dimensional gel electrophoresis and mass spectrometry. Fertil Steril 89(6):1625–1631\nLong X, Jiang P, Zhou L et al (2013) Evaluation of novel serum biomarkers and the proteomic differences of endometriosis and adenomyosis using MALDI-TOF-MS. Arch Gynecol Obstet 288(1):201–205\nXiaoyu L, Weiyuan Z, Ping J et al (2013) Comparative serum proteomic analysis of adenomyosis using the isobaric tags for relative and absolute quantitation technique. Fertil Steril 100(2):505–510\nXiaoyu L, Weiyuan Z, Ping J et al (2014) Serum differential proteomic analysis of endometriosis and adenomyosis by iTRAQ technique. Eur J Obstet Gynecol Reprod Biol 182:62–65\nHerrera J, Henke CA, Bitterman PB (2018) Extracellular matrix as a driver of progressive fibrosis. J Clin Invest 128(1):45–53\nNajafi M, Farhood B, Mortezaee K (2019) Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem 120(3):2782–2790\nBonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15(12):786–801\nTheocharis AD, Manou D, Karamanos NK (2019) The extracellular matrix as a multitasking player in disease. FEBS J 286(15):2830–2869\nKiyama R, Wada-Kiyama Y (2015) Estrogenic endocrine disruptors: Molecular mechanisms of action. Environ Int 83:11–40\nKoike N, Tsunemi T, Uekuri C et al (2013) Pathogenesis and malignant transformation of adenomyosis (review). Oncol Rep 29(3):861–867\nBurridge K (2017) Focal adhesions: a personal perspective on a half century of progress. FEBS J 284(20):3355–3361\nPanera N, Crudele A, Romito I et al (2017) Focal adhesion kinase: insight into molecular roles and functions in hepatocellular carcinoma. Int J Mol Sci 18(1):99\nFunding\nThis work was supported by the Natural Science Foundation of Jiangxi Province under Grant [no. 20181BAB215009]; the National Natural Science Foundation of China under Grant [no. 81660736].\nAuthor information\nAuthors and Affiliations\nContributions\nYL: collected the data and wrote the manuscript. Z-mL: collected the data. LL: performed the experiments. YZ: edited the manuscript. X-yX: performed the experiments. ZZ: analyzed the data. F-YL: analyzed the data. LW: conceive and design the experiments. YX: conceived and designed the experiments, edited the manuscript.\nCorresponding authors\nEthics declarations\nConflict of interest\nThe authors declare that they have no conflict of interest.\nEthical approval\nThis study was approved by the Ethics Committee of Jiangxi Provincial Maternal and Child Health Hospital (registration number: EC-KY-201302, registered on September 18, 2013).\nInformed consent\nBecause previous studies have obtained informed consent from patients, and our work is continued to former research, application for exemption of informed consent was approved by the Ethics Committee of Jiangxi Provincial Maternal and Child Health Hospital.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nLuo, Y., Li, Zm., Li, Lp. et al. ITRAQ-based proteomics analysis of tanshinone IIA on human ectopic endometrial stromal cells of adenomyosis. Arch Gynecol Obstet 303, 1501–1511 (2021). https://doi.org/10.1007/s00404-020-05936-1\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-020-05936-1","source_license":"CC0","license_restricted":false}